PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22.17%
R&D reduction while AXSM shows 0.51% growth. Joel Greenblatt would examine competitive risk.
-22.47%
G&A reduction while AXSM shows 6.79% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-12.79%
Other expenses reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine efficiency.
-22.23%
Operating expenses reduction while AXSM shows 5.81% growth. Joel Greenblatt would examine advantage.
-22.23%
Total costs reduction while AXSM shows 5.81% growth. Joel Greenblatt would examine advantage.
10981.63%
Interest expense growth while AXSM reduces costs. John Neff would investigate differences.
-12.79%
D&A reduction while AXSM shows 4.55% growth. Joel Greenblatt would examine efficiency.
22.24%
EBITDA growth while AXSM declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
22.23%
Operating income growth while AXSM declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-88.23%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
18.34%
Pre-tax income growth while AXSM declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
88.23%
Tax expense growth less than half of AXSM's 200.00%. David Dodd would verify if advantage is sustainable.
18.34%
Net income growth while AXSM declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
32.95%
EPS growth while AXSM declines. John Neff would investigate advantages.
32.95%
Diluted EPS growth while AXSM declines. John Neff would investigate advantages.
21.91%
Share count reduction below 50% of AXSM's 2.52%. Michael Burry would check for concerns.
21.91%
Diluted share reduction below 50% of AXSM's 2.52%. Michael Burry would check for concerns.